Patheon — Q2 2006 Earnings Presentation
10 slides from Patheon's earnings presentation, Jun 2, 2006
Slide 1: Q2 2006 Financial Results Conference Call
Q2 2006 FINANCIAL RESULTS CONFERENCE CALL June 2, 2006 10:00 a.m. (EDT) STRATEGIC RELATIONSHIPS | TECHNOLOGIES | PRODUCTS Presenting on behalf of Patheon • PETER GREEN Chairman of the Board of Directors and Office of the Chief Executive Officer • NICK DIPIETRO President and Chief Operating Officer a
Slide 2: Agenda; Forward-looking Information
Agenda • Overview of Q2 and YTD results (S. Jourard) • Current issues (D. Ludwig) – Q2 performance drivers – Outlook • Business Review (N. DiPietro) – Update on Puerto Rico – Revenue development • Concluding remarks (P. Green) – Performance Enhancement Program – Update on CEO search • Q&A Forward-lo
Slide 3: Q2 2006 Highlights and 1st Half 2006 Highlights
Q2 2006 Highlights • Revenues up 3% to $189.9M • EBITDA of $24.2M (12.8% of revenues) vs. $24.3M (13.2% of revenues) a year ago • Net earnings of $3.0M vs. $3.8M a year ago • EPS of 3.2¢/share vs. 3.4¢/share a year ago 1st Half 2006 Highlights • Revenues up 3% to $347.8M • EBITDA of $38.2M (11.0% of
Slide 4: Current Issues: Performance Highlights
CURRENT ISSUES Performance Highlights Revenues up 20% over Q1 and 3% YOY EBITDA up $10.2M (73%) over Q1, but flat YOY Impact of currency fluctuations – Further strengthening of Canadian dollar relative to U.S. dollar decreased reported EBITDA of Canadian operations by ~$1.6M YOY Effective ta
Slide 5: Earnings Performance: Challenges and Achievements
Earnings performance: Challenges Puerto Rico commercial manufacturing EBITDA declined by ~55% to $4.4M – Reduced revenues and profitability on a large-volume generic product – Added costs to address FDA Warning Letter issues Global PDS EBITDA declined by 31% to $3.4M – Good growth at Cincinnati
Slide 6: Outlook for balance of 2006
Outlook for balance of 2006 Continued improvements in commercial manufacturing revenues in Canada and Europe Lower commercial manufacturing revenues in U.S. relative to 2005 Accelerated PDS revenue growth, driven by Cincinnati and Swindon Second half 2006 revenues expected to be slightly hig
Slide 7: Update on Puerto Rico; Major New Business: Swindon, U.K.
Update on Puerto Rico • FDA re-inspection of Carolina facility – Inspection underway – Awaiting report • Cedfinir ANDA (Omnicef® capsules, 300 mg) – Capsules represent less than 10% of PTI revenues from Omnicef® – Abbott’s compound patent protection extends until May 2007; the company has a formulat
Slide 8: Major New Business: Manati, Puerto Rico
Major New Business: Manati, Puerto Rico Manati, Puerto Rico 1. Global Pharma Client Two products Tech transfer agreement for first product signed Long-term agreements under negotiation Commercial Rx volumes in 2007 Major New Business: Manati, Puerto Rico Manati, Puerto Rico 1. Global Pharma
Slide 9: Conclusion: Performance Enhancement Program
CONCLUSION Performance Enhancement Program Patheon is well established as the market leader in pharmaceutical outsourcing, but we need to improve profitability and cash generation We have initiated a performance enhancement program Program to include quantifiable objectives and timetables that
Slide 10: CEO Succession
CEO Succession Board Succession Committee actively engaged in the search for the new CEO Expect to complete the process during the fourth quarter Work on the performance enhancement program will proceed while the CEO search is underway Committed to swift and decisive action that will improve